The evolving landscape of prostate cancer somatic mutations

Area of Science:

• Genomics
• Oncology
• Cancer Biology

Background:

• Prostate cancer (PCa) somatic mutation landscape rapidly evolving due to genomic sequencing advancements.
• Improved sequencing quality and lower costs enhance understanding of early and late PCa mutations.
• Current knowledge is limited by next-generation sequencing (NGS) assay trade-offs (coverage vs. gene spectrum) and bulk tumor analysis ignoring heterogeneity.

Purpose of the Study:

• To review the evolution of the somatic mutation landscape in prostate cancer during disease progression, considering therapeutic interventions.
• To focus on specific early and late mutations relevant to PCa.
• To use SPOP mutations as a case study for recurrent alterations with potential clinical implications.

Main Methods:

• Review of existing literature on prostate cancer genomics.
• Analysis of mutation data from various sequencing approaches (e.g., NGS, DNA/RNA analysis).
• Focus on studies addressing tumor heterogeneity and therapy-induced mutations.

Main Results:

• Next-generation sequencing (NGS) assays present limitations in capturing the full spectrum of mutations, especially low-frequency ones.
• Accurate detection of certain alterations, like ETS gene fusions, requires integrated DNA and RNA analysis.
• Bulk tumor sample analysis often overlooks critical tumor heterogeneity.

Conclusions:

• The true somatic mutation landscape of prostate cancer is still developing, with ongoing research addressing current limitations.
• Understanding mutation evolution in response to therapy is crucial for personalized PCa treatment.
• Recurrent mutations like SPOP alterations may offer new diagnostic or therapeutic targets.